Abstract
RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. It is therefore imperative to improve their delivery to target sites and reduce their harmful effects on noncancerous cells to harness their full potential. In this study, the role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. It is worth mentioning that delivery systems such as lipid-based delivery systems and exosomes have revolutionized RNAi therapy by reducing their immunogenicity and improving their cellular affinity. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development.
Highlights
Insight Into the Prospects for RNA interference (RNAi) Therapy of CancerZhili Tian 1,2†, Guohui Liang 1,2†, Kunli Cui 3†, Yayu Liang 1,4, Qun Wang 3*, Shuangyu Lv 1, Xiaoxia Cheng 3 and Lei Zhang 3*
Cancer is one of the most fatal diseases with poor prognosis and scarce solutions
Given its target site specificity and therapeutic potential, RNA interference (RNAi) is currently used in many research fields and treatments Since 2018, some RNAi drugs have been approved for sale due to their efficacy and safety (Weng et al, 2019)
Summary
Zhili Tian 1,2†, Guohui Liang 1,2†, Kunli Cui 3†, Yayu Liang 1,4, Qun Wang 3*, Shuangyu Lv 1, Xiaoxia Cheng 3 and Lei Zhang 3*. It can be used to improve the accuracy, efficiency, and stability of treatments, genetic therapies. Challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. The role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
